Researchers Coax Retinal Muller Glia Cells to Become Regenerating Neurons that Function

September 1, 2017: By Joan McKenna

1 Ophthalmic NewsResearchers have coaxed retinal Müller glia cells in an injured mouse eye to become regenerating neurons that become part of the eye’s circuitry, according to a study published July 26 in Nature.

The study, by Tom Reh, PhD, and his team at the UW Medicine in Seattle, was funded in part by the National Eye Institute.

Müller glia cells are retinal cells that support the health and functioning of neighboring neurons and also exhibit regenerative ability.

Earlier work by the team showed that activating a transcription factor called Ascl1 in newborn mice could direct Müller glia to become retinal neurons that activated genes involved in regeneration. However, in older mice, those genes became inaccessible.

Using the anti-cancer agent trichostatin A (TSA) made the genes accessible again, the scientists found.

For this study, the team used an adult mouse model genetically engineered to express Ascl1 in Müller glia in response to tamoxifen, a commonly used breast cancer drug.

They injected the mice with TSA and tamoxifen. Over the next several weeks, the shape and behavior of the cells showed evidence of regeneration.

About two weeks following injury, the cells responded to light as if they were interneurons, retinal cells that transmit signals from photoreceptors to the brain.

The cells also formed functioning synapses, or connections from one neuron to another, and had integrated with retinal cells that convey signals to the brain.

Reh said the approach could be useful for treatment of acute eye injuries and central retinal arterial occlusion. Reh’s lab is investigating other types of regenerative strategies to address all the retinal cell types.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Imprimis’ Q3-2017 Ophthalmic Revenues Increase 60 Percent, Total $4.9 Million

iVeena Completes Phase I/IIa Study of IVMED-10 for Post-Cataract Inflammation

RegeneRx Announces Positive Phase III Results for RGN-259 in Dry Eye

Bill Link, PhD, Joins LENSAR as Board Chairman

Apellis Prices $150 Million Initial Public Offering

Oculentis Recalls Lentis IOLs in Philippines Due to Reports of Postoperative Opacification

Valeant Reports 1 Percent Growth for Bausch + Lomb Segment in Q3-2017

Tivanisiran is Generic Name for Sylentis’ Dry Eye Candidate

Alimera’s Q3-2017 Revenues Increased 18 Percent; Company Sees Expanded Market for Iluvien

Iridex’ Revenues Increase 11 Percent in Q3-2017; 111 Cyclo G6 Systems, 7,800 G6 Probes Shipped

Glaukos’ Net Sales Increase 37 Percent in Q3-2017

Regeneron’s US Eylea Sales Increase 12 Percent in Q3-2017

Second Sight Reports Q3-2017 Net Sales of $1.6 Million, New $122,500 CMS Rate for Argus II

Tear Film Innovations, Exicure, Genisphere Complete Financing Rounds

Opternative Sues Warby Parker Over Online Eye Exams

Bausch + Lomb Receives US FDA Approval for Vyzulta for IOP Reduction in Glaucoma Patients

Allergan Plans Cost Cuts, Takes Impairment Charge as Restasis Generics Loom

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022